SELLAS Life Sciences Group Inc. (SLS) is navigating the latter half of 2025 with multiple clinical programs in motion and a clear focus on acute myeloid leukemia or AML.
The company's development strategy centers on two assets, Galinpepimut-S (GPS), a cancer immunotherapy targeting the WT1 antigen, and SLS009, a CDK9 inhibitor, both of which are being evaluated in AML across different stages of disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com